Salvage Therapy With Selpercatinib for
Case Report
Leptomeningeal disease
NSCLC
Pralsetinib
RET fusion
Selpercatinib
Journal
JTO clinical and research reports
ISSN: 2666-3643
Titre abrégé: JTO Clin Res Rep
Pays: United States
ID NLM: 101769967
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
22
06
2023
revised:
18
09
2023
accepted:
26
09
2023
medline:
30
11
2023
pubmed:
30
11
2023
entrez:
30
11
2023
Statut:
epublish
Résumé
Selpercatinib and pralsetinib are RET inhibitors with substantial activity in advanced
Identifiants
pubmed: 38034820
doi: 10.1016/j.jtocrr.2023.100581
pii: S2666-3643(23)00124-8
pmc: PMC10687334
doi:
Types de publication
Case Reports
Langues
eng
Pagination
100581Informations de copyright
© 2023 The Authors.
Références
J Clin Oncol. 2023 Jan 10;41(2):385-394
pubmed: 36122315
Transl Lung Cancer Res. 2021 Jan;10(1):487-495
pubmed: 33569330
JTO Clin Res Rep. 2021 Dec 28;3(2):100271
pubmed: 35252894
Ther Adv Med Oncol. 2021 Jun 11;13:17588359211019675
pubmed: 34178121
J Thorac Oncol. 2010 Jul;5(7):1105-6
pubmed: 20581580
Transl Lung Cancer Res. 2019 Nov;8(Suppl 3):S318-S320
pubmed: 31857955
Mol Clin Oncol. 2016 Oct;5(4):488-490
pubmed: 27699048
Ann Oncol. 2022 Nov;33(11):1168-1178
pubmed: 35973665
JCO Precis Oncol. 2019;3:
pubmed: 31485557
Clin Lung Cancer. 2022 Jan;23(1):e5-e8
pubmed: 34246540